Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 1
1948 1
1950 5
1951 4
1952 4
1953 6
1954 2
1955 3
1956 5
1957 6
1958 3
1959 13
1960 15
1961 3
1962 7
1963 7
1964 3
1965 7
1966 3
1967 11
1968 6
1969 4
1970 13
1972 3
1973 8
1974 3
1975 8
1976 5
1977 5
1978 2
1979 6
1980 12
1981 7
1982 5
1983 5
1984 2
1985 8
1986 7
1987 13
1988 7
1989 9
1990 10
1991 12
1992 12
1993 12
1994 16
1995 20
1996 18
1997 10
1998 17
1999 18
2000 19
2001 22
2002 30
2003 21
2004 34
2005 28
2006 17
2007 30
2008 38
2009 39
2010 44
2011 32
2012 48
2013 55
2014 52
2015 56
2016 52
2017 65
2018 76
2019 80
2020 93
2021 103
2022 100
2023 95
2024 71

Text availability

Article attribute

Article type

Publication date

Search Results

1,529 results

Results by year

Filters applied: . Clear all
Page 1
IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation.
Faas M, Ipseiz N, Ackermann J, Culemann S, Grüneboom A, Schröder F, Rothe T, Scholtysek C, Eberhardt M, Böttcher M, Kirchner P, Stoll C, Ekici A, Fuchs M, Kunz M, Weigmann B, Wirtz S, Lang R, Hofmann J, Vera J, Voehringer D, Michelucci A, Mougiakakos D, Uderhardt S, Schett G, Krönke G. Faas M, et al. Among authors: fuchs m. Immunity. 2021 Nov 9;54(11):2531-2546.e5. doi: 10.1016/j.immuni.2021.09.010. Epub 2021 Oct 12. Immunity. 2021. PMID: 34644537 Free article.
[Dysphagia].
Meuret S, Dietz A, Fuchs M. Meuret S, et al. Among authors: fuchs m. Laryngorhinootologie. 2014 Feb;93(2):121-35; quiz 136-7. doi: 10.1055/s-0033-1363679. Epub 2014 Jan 29. Laryngorhinootologie. 2014. PMID: 24477436 Review. German.
A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study.
Fagan A, Gavis EA, Gallagher ML, Mousel T, Davis B, Puri P, Sterling RK, Luketic VA, Lee H, Matherly SC, Sanyal AJ, Stravitz RT, Patel V, Siddiqui MS, Asgharpour A, Fuchs M, Thacker L, Bajaj JS. Fagan A, et al. Among authors: fuchs m. J Hepatol. 2023 Feb;78(2):312-321. doi: 10.1016/j.jhep.2022.09.009. Epub 2022 Sep 22. J Hepatol. 2023. PMID: 36152764 Clinical Trial.
Reply by Authors.
Meier KM, Mata C, Kaar JL, Rensing AJ, Dudley AG, Carrasco A Jr, Drzewiecki BA, VanderBrink BA, Streur CS, Bagli DJ, Chalmers DJ, Wilcox DT, Yerkes EB, Lau GA, Vricella GJ, Hecht SL, Copp HL, Pohl HG, Franco I, Ahn J, Wiener JS, Singer JS, Long CJ, Keays MA, Daugherty MR, Fuchs ME, Austin PF, Wu CQ, Zee RS, Misseri R, Tanaka ST, Bauer SB, Rove KO. Meier KM, et al. Among authors: fuchs me. J Urol. 2024 Jul;212(1):175-176. doi: 10.1097/JU.0000000000004034. Epub 2024 May 14. J Urol. 2024. PMID: 38743826 No abstract available.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Among authors: fuchs m. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. Lancet Oncol. 2021. PMID: 33539742 Clinical Trial.
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P. Eichenauer DA, et al. Among authors: fuchs m. Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10. Lancet Oncol. 2017. PMID: 29133014 Clinical Trial.
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Borchmann P, et al. Among authors: fuchs m. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. Lancet. 2024. PMID: 38971175 Free article. Clinical Trial.
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Kunzmann V, et al. Among authors: fuchs m. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Younossi ZM, Alqahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome PN, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. Younossi ZM, et al. Among authors: fuchs m. J Hepatol. 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18. J Hepatol. 2024. PMID: 37984709
NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritis.
Shen P, Serve S, Wu P, Liu X, Dai Y, Durán-Hernández N, Nguyen DTM, Fuchs M, Maleitzke T, Reisener MJ, Dzamukova M, Nussbaumer K, Brunner TM, Li Y, Holecska V, Heinz GA, Heinrich F, Durek P, Katsoula G, Gwinner C, Jung T, Zeggini E, Winkler T, Mashreghi MF, Pumberger M, Perka C, Löhning M. Shen P, et al. Among authors: fuchs m. Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2207993120. doi: 10.1073/pnas.2207993120. Epub 2023 Jul 10. Proc Natl Acad Sci U S A. 2023. PMID: 37428931 Free PMC article.
1,529 results